- Case report
- Open Access
Ileocaecal recurrence of Merkel cell carcinoma of the skin: a case report
© Cheung et al; licensee BioMed Central Ltd. 2010
Received: 4 November 2009
Accepted: 8 February 2010
Published: 8 February 2010
Merkel cell carcinoma is an uncommon skin malignancy that has a high propensity for metastatic spread. A systematic literature search identified 17 cases describing metastasis to the gastrointestinal tract, with 7 cases involving the small or large bowel. To the best of our knowledge, this is the only case described of Merkel cell carcinoma metastasising to the ileocaecal valve.
We present a 74-year-old Filipino woman diagnosed with Merkel cell carcinoma of the skin with regional node involvement. Following excision and radiotherapy, the tumour recurred with metastasis to the ileocaecal valve. The patient died 28 months after the initial diagnosis.
The prognosis of metastatic Merkel cell carcinoma is poor. Currently the optimal management for metastatic disease is unclear and lacks a firm evidence base due to the small number of cases reported.
Merkel cell carcinoma (MCC) is an uncommon and highly aggressive skin malignancy. It arises from Merkel cells at the dermo-epidermal junction, which are of neuroendocrine origin. Since its first description by Toker in 1972 , more than 2000 cases have been reported in the literature . Its aetiology is not entirely known, but there is convincing evidence for the role of ultraviolet radiation. MCC has a predilection for sun-exposed areas of the body and is associated with other sun-related skin cancers such as basal cell carcinoma and squamous cell carcinoma. The occurrence of MCC in areas that are not exposed to the sun suggests additional causes. Reports of MCC in organ transplant, human immunodeficiency virus (HIV) infection and lymphohemopoietic malignancies, such as chronic lymphocytic leukemia, implicate a role for immunosuppression [2, 3].
The incidence of MCC is 0.23 per 100,000 in Caucasians , which is about 20 times the incidence compared to the Afro-Caribbean population. MCC is also more common in older men with a mean age of diagnosis at 69 years old . In a review of 1024 patients, the primary tumour was found in the head and neck in 40%, in the extremities in 33%, and in the trunk in 23% of patients . At presentation the regional lymph nodes are involved in around 25% of cases, and distant metastases are found in 4% . Metastasis usually occurs in the skin (28%), lymph nodes (27%), liver (13%), lung (10%), bone (10%), and the brain (6%) [2, 4]. Metastasis can also involve the gastrointestinal (GI) tract in very rare cases.
Reported cases of gastrointestinal metastases of Merkel call cancer.
Site of Metastasis
Li M and Liu C 
Cubiella J, et al. 
Idowu M, et al. 
Wolov K, et al. 
Krasagakis K, et al. 
Stomach, small bowel
Canales L, et al. 
Stomach, small bowel
Shalhub S, et al. 
Stomach, descending colon
Hizawa K, et al. 
Stomach, distal duodenum, pancreas
Olivero G, et al. 
Naunton M and Henderson RG 
Foster R, et al. 
Huang W S, et al. 
Paterson C, et al. 
Adsay NV, et al. 
Bachmann J, et al. 
Dim DC, et al. 
Ouellett JR, et al. 
A 74-year-old Filipino woman presented with a skin lesion in her right antecubital fossa. It was a 2 cm soft, mobile, well-circumscribed mass which appeared over three weeks. Suspecting liposarcoma, her general practitioner referred her to the hospital's surgical team. Urgent excision biopsy revealed metastatic carcinoma expressing neuroendocrine markers. Immunohistochemical staining showed that the patient had a strong positivity for CK20, which was a sensitive and specific marker for Merkel cell carcinoma . She was also highly positive for chromogranin, synaptophysin and CD117, thus confirming the diagnosis of MCC. She showed no staining for TTF-1, which excluded lung primary small cell carcinoma.
Subsequent computed tomography (CT) examinations of her chest, abdomen and pelvis identified significant right-sided axillary lymphadenopathy, with the largest node measuring 6 cm in diameter. The CT was conducted two months after our patient's initial clinical presentation, and the axillary adenopathy was now clinically apparent. There was no hilar or mediastinal lymphadenopathy observed. Her lungs, bones and intra-abdominal organs were all clear of metastasis. A positron emission tomography (PET) body scan showed high uptake in her right axilla, with moderate heterogeneous uptake in some bowel loops. This was thought to represent inflammatory change in the presence of diverticular disease. No definite primary source, however, was identified.
At axillary lymph node dissection, eight of 26 lymph nodes, as well as the axillary vein, were found to contain tumour. Adjuvant radiotherapy was administered to our patient's axillary and subclavicular regions (42 Gy, 21 fractions, 31 days), but it was postponed until six months postoperatively due to the presence of seroma and lymphoedema. Surgical and oncological follow-up at intervals of two, three and six months found our patient asymptomatic.
At colonoscopy a tumour was seen at 70 cm from our patient's anus. The morphology and immunoprofile of the biopsy confirmed it as a recurrence of MCC. Markers for colorectal cancer (CA 19.9, CEA) were negative.
Prior to chemotherapy our patient became increasingly frail and deteriorated rapidly. She died of bronchopneumonia 28 months after the initial diagnosis of metastatic Merkel cell carcinoma.
Merkel cell carcinoma has been described as one the most aggressive of the skin malignances [4, 22]. In Medina-Franco's review of 1024 cases, this metastatic disease affects 31% of patients either at presentation or at later stage . Excluding the patients with metastasis at presentation, 31% develop local recurrence, and the average disease-free interval is only 7.4 months . Of the factors related to prognosis in MCC, lymph node status has been shown to be most consistent with clinical outcome [22–25]. This is reflected in the staging of the disease, where stage I describes lesions confined to the skin, stage II describes the involvement of regional nodes, and stage III describes the presence of metastasis. Five-year survival rates are 64%, 47% and 11%, respectively [2, 23, 25, 26]. This compares with a 7% to 19% survival rate for malignant melanoma with metastasis .
A retrospective review of 109 patients by Allen et al. revealed that in patients with stage I disease, the tumour size at presentation was also an independent predictor of survival. In view of this, a 4-tiered system is also widely used to reflect a more accurate prognosis. It classifies patients with lymph node-negative cutaneous disease of <2 cm as stage I, and cutaneous lesions of >2 cm as stage II. Lymph node-positive disease is classified as stage III, while the presence of distant metastases is stage IV .
The treatment of choice for MCC is surgical excision with wide margins. There is no consensus on the width of excision required, but many surgical series have suggested margins of 2.5 cm to 3 cm . There is evidence to show, however, that low local recurrence rates (8%) can be achieved after margin-negative excisions with margins that averaged 1.1 cm. This has lead to the suggestion that larger excision margins of at least 2 cm should be reserved for larger lesions of >2 cm in diameter .
Given that MCC occurs so frequently in the head and the neck, where wide local excision or even Moh's surgery may be difficult, the role of adjuvant therapy has been much considered. One large case series review involving over 400 patients found that radiotherapy improves local control from a recurrence rate of 52% to 10.5% . Some studies, however, showed contrary results where radiotherapy did not improve recurrence rates in patients with node-negative diseases. They instead recommend that adjuvant therapy may be beneficial in patients with clinically positive nodes or those who have undergone elective or sentinel node biopsy with positive nodes .
Due to the importance of lymph node status in treatment outcome, sentinel lymph node biopsy (SLNB) as a staging procedure is considered standard practice in some centers, and its use has been recommended by many others. A number of studies have reported SLNB positivity rate of 20% to 30% involving patients who are clinically lymph node negative [23, 28]. Where micrometastasis is found on SLNB, however, complete lymph node dissection is considered as first-line management, while radiotherapy is second-line [26, 28].
As a neuroendocrine tumour, MCC demonstrates chemosensitivity to agents used in treating small-cell lung cancer, such as carboplatin, vincristine and etoposide. The role of chemotherapy, however, is much less established than that of radiotherapy. There is some support for its use either as a radiation sensitizer or as adjuvant therapy in high-risk cases with the disease at stage II or above . At stage IV of the disease chemotherapy has shown high but relatively short response rates of 8 months on the average, and does not appear to add significantly where the median survival in metastasis is 10 months .
Overall, the optimal management for patients with MCC remains unclear. Treatment is often guided by opinion rather than evidence-based practice . Bichakjian et al. proposed an algorithm reflecting the evidence as discussed above . Again it suggests wide local excision margins of 1 cm for lesions measuring <2 cm, and 1 cm to 2 cm for lesions measuring >2 cm. Radiotherapy is best used when clear margins cannot be obtained. Furthermore, sentinel node biopsy should be performed in all instances.
Meanwhile, negative SLNB should be observed at intervals between 2 to 6 months for 2 years, with decreasing intervals thereafter. The use of imaging should be guided by clinical findings rather than by routine due to high false-positive rates, and the lack of survival benefit in detecting asymptomatic distant metastases. Positive sentinel nodes should be treated with complete node dissection and radiation depending on the level of the nodal disease. Once there is involvement in distant sites, therapy is primarily for palliation. The literature on the management of recurrent and metastatic diseases is particularly limited. The only consensus seems to be that the outcome of high stage MCC is gravely unfavorable.
The management of Merkel cell carcinoma poses a challenge to clinicians for several reasons. For one, it is aggressive and has a propensity for spread and recurrence. Optimal therapy in high stage disease or recurrence is less clearly established. Its low incidence warrants the collaboration of different institutions to produce large multicenter controlled trials in order to compare responses to different treatment modalities. At any stage, its management is likely to benefit from a multidisciplinary approach, which is highlighted in this case report.
Written informed consent was obtained from the patient's next-of-kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Systematic search algorithm employed.
Literature search was conducted using MeSH terms "oesophagus" [All Fields] OR "esophagus" [All Fields] OR "stomach" [All Fields] OR "duodenum" [All Fields] OR "jejunum" [All Fields] OR "ileum" [All Fields] OR "bowel" [All Fields] OR "intestine" [All Fields] OR "intestinal" [All Fields] OR "caecum" [All Fields] OR "rectum" [All Fields] OR "rectal" [All Fields] OR "colon" [All Fields] AND "merkel cell" [All Fields].
This produced 61 results on PubMed of which 17 are reports of metastatic Merkel cell carcinoma in the gastrointestinal tract (excluding the liver).
- Toker C: Trabecular carcinoma of the skin. Arch Dermatol. 1972, 105 (1): 7-10. 10.1001/archderm.105.1.107.View ArticleGoogle Scholar
- Poulsen M: Merkel-cell carcinoma of the skin. Lancet Oncol. 2004, 5 (10): 593-599. 10.1016/S1470-2045(04)01593-1.View ArticlePubMedGoogle Scholar
- Ziprin P, Smith S, Salerno G, Rosin RD: Two cases of Merkel cell tumour arising in patients with chronic lymphocytic leukemia. Br J Dermatol. 2000, 142 (3): 525-528. 10.1046/j.1365-2133.2000.03370.x.View ArticlePubMedGoogle Scholar
- Medina-Franco H, Urist MM, Fiveash J, Heslin MJ, Bland KI, Beenken SW: Multimodality treatment of Merkel cell carcinoma: case series and literature review of 1024 cases. Ann Surg Oncol. 2001, 8 (3): 204-208. 10.1007/s10434-001-0204-4.View ArticlePubMedGoogle Scholar
- Shalhub S, Clarke L, Morgan MB: Metastatic Merkel cell carcinoma masquerading as colon cancer. Gastrointest Endosc. 2004, 60 (5): 856-858. 10.1016/S0016-5107(04)02173-X.View ArticlePubMedGoogle Scholar
- Krasagakis K, Almond-Roesler B, Zouboulis CC, Tebbe B, Wartenberg E, Wolff KD, Orfanos CE: Merkel cell carcinoma: report of 10 cases with emphasis on clinical course, treatment, and in vitro drug sensitivity. J Am Acad Dermatol. 1997, 36 (5 Pt 1): 727-732. 10.1016/S0190-9622(97)80325-8.View ArticlePubMedGoogle Scholar
- Canales LI, Parker A, Kadakia S: Upper gastrointestinal bleeding from Merkel cell carcinoma. Am J Gastroenterol. 1992, 87 (10): 1464-1466.PubMedGoogle Scholar
- Hizawa K, Kurihara S, Nakamori M, Nakahara T, Matsumoto T, Iida M: An autopsy case of Merkel cell carcinoma presenting aggressive intra-abdominal metastasis and duodenal obstruction. Nippon Shokakibyo Gakkai Zasshi. 2007, 104 (9): 1383-1386.PubMedGoogle Scholar
- Naunton Morgan TC, Henderson RG: Small bowel metastases from a Merkel cell tumor. Br J Radiol. 1985, 58 (696): 1212-1213. 10.1259/0007-1285-58-696-1212.View ArticlePubMedGoogle Scholar
- Foster R, Stevens G, Egan M: An unusual pattern of metastases from Merkel cell carcinoma. Australas Radiol. 1994, 38 (3): 231-232. 10.1111/j.1440-1673.1994.tb00184.x.View ArticlePubMedGoogle Scholar
- Li M, Liu C: Cytokeratin 20 confirms Merkel cell metastasis to stomach. Appl Immunohistochem Mol Morpho. 2004, 12 (4): 346-349. 10.1097/00129039-200412000-00010.View ArticleGoogle Scholar
- Cubiella J, Salgado M, Riu M, Garcia-Mata J, Sanchez E, Diez MS, Rodriguez R, Vega M: Gastric metastatis due to Merkel cell carcinoma: a rare cause of gastric bleeding. Rev Esp Enferm Dig. 2004, 96 (2): 150-151. 10.4321/S1130-01082004000200011.View ArticlePubMedGoogle Scholar
- Idowu MO, Contos M, Gill S, Powers C: Merkel cell carcinoma: a report of gastrointestinal metastasis and review of the literature. Arch Pathol Lab Med. 2003, 127 (3): 367-369.PubMedGoogle Scholar
- Wolov K, Tully O, Mercogliano G: Gastric metastasis of Merkel cell carcinoma. Clin Gastroenterol Hepatol. 2009, 7 (3): A26-10.1016/j.cgh.2008.07.024.View ArticlePubMedGoogle Scholar
- Olivero G, Franchello A, Pacchioni D, Enrichens F, Mao P, Benedetto G: A rare case of Merkel's tumor with intestinal metastases. Ann Ital Chir. 1990, 61 (3): 277-280.PubMedGoogle Scholar
- Huang WS, Lin PY, Lee IL, Chin CC, Wang JY, Yang WG: Metastatic Merkel cell carcinoma in the rectum: report of a case. Dis Colon Rectum. 2007, 50 (11): 1992-1995. 10.1007/s10350-006-0879-5.View ArticlePubMedGoogle Scholar
- Paterson C, Musselman L, Chorneyko K, Reid S, Rawlinson J: Merkel cell (neuroendocrine) carcinoma of the anal canal: report of a case. Dis Colon Rectum. 2003, 46 (5): 676-678. 10.1007/s10350-004-6630-1.View ArticlePubMedGoogle Scholar
- Adsay NV, Andea A, Basturk O, Kilinc N, Nassar H, Cheng JD: Secondary tumors of the pancreas: an analysis of a surgical and autopsy database and review of the literature. Virchows Arch. 2004, 444 (6): 527-535. 10.1007/s00428-004-0987-3.View ArticlePubMedGoogle Scholar
- Bachmann J, Kleeff J, Bergmann F, Shrikhande SV, Hartschuh W, Buchler MW, Friess H: Pancreatic metastasis of Merkel cell carcinoma and concomitant insulinoma: case report and literature review. World J Surg Oncol. 2005, 3: 58-10.1186/1477-7819-3-58.View ArticlePubMedPubMed CentralGoogle Scholar
- Dim DC, N20. Idowu MO, Contos M, Gill S, Powers C: Merkel cell carcinoma: a report of gastrointestinal metastasis and review of the literature. Arch Pathol Lab Med. 2003, 127 (3): 367-369.Google Scholar
- Ouellette JR, Woodyard L, Toth L, Termuhlen PM: Merkel cell carcinoma metastatic to the head of the pancreas. JOP. 2004, 5 (2): 92-96.PubMedGoogle Scholar
- Eng TY, Boersma MG, Fuller CD, Goytia V, Jones WE, Joyner M, Nguyen DD: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol. 2007, 30 (6): 624-636. 10.1097/COC.0b013e318142c882.View ArticlePubMedGoogle Scholar
- Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG: Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005, 23 (10): 2300-2309. 10.1200/JCO.2005.02.329.View ArticlePubMedGoogle Scholar
- Pectasides D, Pectasides M, Psyrri A, Koumarianou A, Xiros N, Pectasides E, Gaglia A, Lianos E, Papaxoinis G, Lampadiari V, Economopoulos T: Cisplatin-based chemotherapy for Merkel cell carcinoma of the skin. Cancer Invest. 2006, 24 (8): 780-785. 10.1080/07357900601062354.View ArticlePubMedGoogle Scholar
- Allen PJ, Zhang ZF, Coit DG: Surgical management of Merkel cell carcinoma. Ann Surg. 1999, 229 (1): 97-105. 10.1097/00000658-199901000-00013.View ArticlePubMedPubMed CentralGoogle Scholar
- Pectasides D, Pectasides M, Economopoulos T: Merkel cell cancer of the skin. Ann Oncol. 2006, 17 (10): 1489-1495. 10.1093/annonc/mdl050.View ArticlePubMedGoogle Scholar
- Mosca PJ, Teicher E, Nair SP, Pockaj BA: Can surgeons improve survival in stage IV melanoma?. J Surg Oncol. 2008, 97 (5): 462-468. 10.1002/jso.20950.View ArticlePubMedGoogle Scholar
- Bichakjian CK, Lowe L, Lao CD, Sandler HM, Bradford CR, Johnson TM, Wong SL: Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer. 2007, 110 (1): 1-12. 10.1002/cncr.22765.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.